Datamonitor expects the antithrombotics market to peak at just over $20 billion in 2012, across the seven major markets. The growth will be driven by the uptake of the novel oral anticoagulants - Bayer's Xarelto and BI's Rendix - which are expected to launch simultaneously, in 2008.
Scope
Event-driven sales forecasts for 2007-16 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.
Country and market specific issues that will impact sales opportunities and market landscape, including key patent expiries and product launches.
Case studies assessing the possibility that a novel, oral anticoagulant may replace warfarin; and detailing the Plavix patent dispute with Apotex.
Analysis of the main antithrombotics drugs, with a qualitative assessment of their future market potential, backed-up by thought-leader opinion.
Report Highlights The antithrombotics market is mature, however, the possibility of engineering a replacement for warfarin, or a side-effect free, oral anticoagulant suitable for chronic anticoagulation does represent an attractive opportunity for R&D expenditure. The simultaneous launch of FXa inhibitor Xarelto, and DTI, Rendix, will occur in 2008.
Cost containment initiatives, promoting the prescription of generic drugs, are being introduced across the seven major markets and will constrain growth. However, a paradigm shift towards thrombosis prophylaxis, will expand the oral anticoagulant markets in terms of stroke prevention in atrial fibrillation and post-surgical patient populations.
Sanofi-Aventis's Lovenox (enoxaparin) is the dominant LMWH, generating sales of $3.0 billion in 2006 and thereby accounting for 72% of the overall heparin market and 80% of the LMWH market. However, the Lovenox patent expires in 2012 and so Lovenox revenues will be subject to generic erosion over the forecast period.
Reasons to Purchase
Quantify the future size of the antithrombotics market and identify opportunities for new products.
Learn how the premature expiry of the Plavix patent would have shaped the market and understand why Apotex chose to launch a generic at risk.
Understand the barriers to uptake that novel anticoagulants may experience in attempting to replace warfarin.
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
